{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:18:40Z","timestamp":1776381520261,"version":"3.51.2"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>Emicizumab promotes efficacious hemostasis in persons with hemophilia A persons with hemophilia A with and without inhibitors. Primary analyses of real-world data and clinical trials have shown emicizumab efficacy and safety; however, long-term data are limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This retrospective study was conducted to assess real-world long-term outcomes of pediatric patients on emicizumab in our hemophilia center between the period of February 2018 and September 2023. Relevant demographic and clinical data were gathered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Seventy-eight patients were enrolled. Previously untreated patients and minimally treated patients accounted for 14.1% and 10.3% of our recruited patients, respectively. One of 5 patients with active inhibitors experienced a single recombinant activated factor VII-treated bleeding episode while on emicizumab prophylaxis. Twenty-eight (28\/78) patients underwent surgical\/dental procedures without bleeding complications except for 2 patients (7.1%). Thirty-three patients experienced 62 factor-treated bleeding episodes with only 11 imaging-confirmed joint\/muscle bleeding episodes among 8 patients. No major safety concerns were reported in the study and emicizumab was discontinued in 5 patients (2 for antidrug antibody development, 2 for joint bleeding, and 1 for non-compliance).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Emicizumab prophylaxis was well tolerated with no new safety concerns, and 45 patients (57.7%) of our cohort exhibited zero-treated bleeds, which was comparable to other published experiences.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000002997","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:31:04Z","timestamp":1737739864000},"page":"e83-e89","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["A 5-Year Single-center Experience on the Use of Emicizumab Prophylaxis in Children With Severe Hemophilia A With and Without Factor VIII Inhibitors"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2835-5068","authenticated-orcid":false,"given":"Esraa Mohamed","family":"Ahmed Hasan","sequence":"first","affiliation":[{"name":"Department of Paediatric Haematology, NHS Foundation Trust, Birmingham Children\u2019s Hospital, Birmingham, UK"},{"name":"Department of Pediatrics, Hematology and Oncology Unit, Ain Shams University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayashree","family":"Motwani","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology, NHS Foundation Trust, Birmingham Children\u2019s Hospital, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1160\/TH08-07-0483","article-title":"Prophylaxis in people with hemophilia","volume":"101","author":"Coppola","year":"2009","journal-title":"Thromb Haemost"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16704","article-title":"British Society for Haematology. Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B","volume":"190","author":"Rayment","year":"2020","journal-title":"Br J Haematol"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2147\/JBM.S260923","article-title":"Clinical utility of subcutaneous factor VIII replacement therapies in hemophilia a: a review of the evidence","volume":"12","author":"Dargaud","year":"2021","journal-title":"J Blood Med"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic co factor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/hae.13641","article-title":"Emicizumab: review of the literature and critical appraisal","volume":"25","author":"Rodriguez-Merchan","year":"2019","journal-title":"Haemophilia"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s40265-019-01200-2","article-title":"Emicizumab: a review in haemophilia A","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/jth.14556","article-title":"Emicizumab and thrombosis: the story so far","volume":"17","author":"Makris","year":"2019","journal-title":"J Thromb Haemost"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtha.2023.01.010","article-title":"Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021","volume":"21","author":"Maria","year":"2023","journal-title":"J Thromb Haemost"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.V130.Suppl_1.85.85","article-title":"HAVEN 2 updated analysis: multi center, open-label, phase 3 study to evaluate efficacy, safety and pharmacokinetics of subcutaneous administration of Emicizumab prophylaxis in pediatric patients with hemophilia A with inhibitors","volume":"130","author":"Young","year":"2017","journal-title":"Blood"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1186\/s12887-022-03546-1","article-title":"Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab","volume":"22","author":"Glonnegger","year":"2022","journal-title":"BMC Pediatr"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"992267","DOI":"10.3389\/fped.2022.992267","article-title":"Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China","volume":"10","author":"Liu","year":"2022","journal-title":"Front Pediatr"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/hae.13287","article-title":"The haemtrack home therapy reporting system: design, implementation, strengths, and weaknesses: a report from UK Haemophilia Centre Doctors Organisation","volume":"23","author":"Hay","year":"2017","journal-title":"Haemophilia"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/hae.14381","article-title":"Immune tolerance induction in severe haemophilia A: a UKHCDO inhibitor and paediatric working party consensus update","volume":"27","author":"Hart","year":"2021","journal-title":"Haemophilia"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"e28942","DOI":"10.1002\/pbc.28942","article-title":"Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab","volume":"68","author":"Garcia","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jha2.832","article-title":"Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: a single-center experience in Bangladesh","volume":"5","author":"Tory","year":"2024","journal-title":"eJHaem"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1160\/TH15-12-0964","article-title":"Age dependency for coagulation parameters in paediatric populations. Results of a multicentre study aimed at defining the age-specific reference ranges","volume":"116","author":"Toulon","year":"2016","journal-title":"Thromb Haemost"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/hae.14762","article-title":"Emicizumab prophylaxis in haemophilia A with inhibitors: three years follow-up from the UK Haemophilia Centre Doctors\u2019 Organisation (UKHCDO)","volume":"29","author":"Wall","year":"2023","journal-title":"Haemophilia"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/hae.14642","article-title":"Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study","volume":"28","author":"Kiialainen","year":"2022","journal-title":"Haemophilia"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"2166334","DOI":"10.1080\/16078454.2023.2166334","article-title":"Expert opinion paper on the treatment of hemophilia a with emicizumab","volume":"28","author":"L\u00f3pez-Jaime","year":"2023","journal-title":"Hematology"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"1155853","DOI":"10.3389\/fped.2023.1155853","article-title":"Management of children with hemophilia A on emicizumab who need surgery","volume":"11","author":"Belletrutti","year":"2023","journal-title":"Front Pediatr"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/jcm12062317","article-title":"Safe and successful surgical outcome in persons with hemophilia A with and without inhibitors treated with emicizumab: a large, single center, real-world experience","volume":"12","author":"Castaman","year":"2023","journal-title":"J Clin Med"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T20:03:26Z","timestamp":1748376206000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002997","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"2024-08-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}